|
1
|
Long H, Li Q, Wang Y, Li Q, Liu T and Peng
J: Effective combination gene therapy using CEACAM6-shRNA and the
fusion suicide gene yCDglyTK for pancreatic carcinoma in vitro. Exp
Ther Med. 5:155–161. 2013.
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bond-Smith G, Banga N, Hammond TM and
Imber CJ: Pancreatic adenocarcinoma. BMJ. 344:e24762012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arlt A, Gehrz A, Müerköster S, Vorndamm J,
Kruse ML, Fölsch UR and Schäfer H: Role of NF-kappaB and Akt/PI3K
in the resistance of pancreatic carcinoma cell lines against
gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barnett T, Goebel SJ, Nothdurft MA and
Elting JJ: Carcinoembryonic antigen family: Characterization of
cDNAs coding for NCA and CEA and suggestion of nonrandom sequence
variation in their conserved loop-domains. Genomics. 3:59–66. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuroki M, Matsushita H, Matsumoto H,
Hirose Y, Senba T and Yamamoto T: Nonspecific cross-reacting
antigen-50/90 (NCA-50/90) as a new tumor marker. Anticancer Res.
19(6C): 5599–5606. 1999.
|
|
8
|
Blumenthal RD, Hansen HJ and Goldenberg
DM: Inhibition of adhesion, invasion, and metastasis by antibodies
targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen).
Cancer Res. 65:8809–8817. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Poola I, Shokrani B, Bhatnagar R, DeWitty
RL, Yue Q and Bonney G: Expression of carcinoembryonic antigen cell
adhesion molecule 6 oncoprotein in atypical ductal hyperplastic
tissues is associated with the development of invasive breast
cancer. Clin Cancer Res. 12:4773–4783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blumenthal RD, Leon E, Hansen HJ and
Goldenberg DM: Expression patterns of CEACAM5 and CEACAM6 in
primary and metastatic cancers. BMC Cancer. 7:22007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duxbury MS, Matros E, Ito H, Zinner MJ,
Ashley SW and Whang EE: Systemic siRNA-mediated gene silencing: A
new approach to targeted therapy of cancer. Ann Surg. 240:667–674;
discussion 675–676. 2004.PubMed/NCBI
|
|
12
|
Strickland LA, Ross J, Williams S, Ross S,
Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P,
et al: Preclinical evaluation of carcinoembryonic cell adhesion
molecule (CEACAM) 6 as potential therapy target for pancreatic
adenocarcinoma. J Pathol. 218:380–390. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Li C, Yang D, Jian XC and Jiang
CH: Clinico-pathological significance of MHC-I type
chain-associated protein A expression in oral squamous cell
carcinoma. Asian Pac J Cancer Prev. 13:715–718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li YH, Liu Y, Li YD, Liu YH, Li F, Ju Q,
Xie PL and Li GC: GABA stimulates human hepatocellular carcinoma
growth through overexpressed GABAA receptor theta subunit. World J
Gastroenterol. 18:2704–2711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hammarström S: The carcinoembryonic
antigen (CEA) family: Structures, suggested functions and
expression in normal and malignant tissues. Semin Cancer Biol.
9:67–81. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jantscheff P, Terracciano L, Lowy A,
Glatz-Krieger K, Grunert F, Micheel B, Brümmer J, Laffer U, Metzger
U, Herrmann R, et al: Expression of CEACAM6 in resectable
colorectal cancer: A factor of independent prognostic significance.
J Clin Oncol. 21:3638–3646. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lewis-Wambi JS, Cunliffe HE, Kim HR,
Willis AL and Jordan VC: Overexpression of CEACAM6 promotes
migration and invasion of oestrogen-deprived breast cancer cells.
Eur J Cancer. 44:1770–1779. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duxbury MS, Ito H, Benoit E, Waseem T,
Ashley SW and Whang EE: A novel role for carcinoembryonic
antigen-related cell adhesion molecule 6 as a determinant of
gemcitabine chemo-resistance in pancreatic adenocarcinoma cells.
Cancer Res. 64:3987–3993. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ordoñez C, Screaton RA, Ilantzis C and
Stanners CP: Human carcinoembryonic antigen functions as a general
inhibitor of anoikis. Cancer Res. 60:3419–3424. 2000.PubMed/NCBI
|
|
20
|
Zhu Z, Sanchez-Sweatman O, Huang X,
Wiltrout R, Khokha R, Zhao Q and Gorelik E: Anoikis and metastatic
potential of cloudman S91 melanoma cells. Cancer Res. 61:1707–1716.
2001.PubMed/NCBI
|
|
21
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: CEACAM6 gene silencing impairs anoikis resistance and
in vivo metastatic ability of pancreatic adenocarcinoma cells.
Oncogene. 23:465–473. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Duxbury MS, Ito H, Benoit E, Ashley SW and
Whang EE: CEACAM6 is a determinant of pancreatic adenocarcinoma
cellular invasiveness. Br J Cancer. 91:1384–1390. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takeichi M: Cadherins in cancer:
Implications for invasion and metastasis. Curr Opin Cell Biol.
5:806–811. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Birchmeier W and Behrens J: Cadherin
expression in carcinomas: Role in the formation of cell junctions
and the prevention of invasiveness. Biochim Biophys Acta.
1198:11–26. 1994.PubMed/NCBI
|
|
25
|
Hartwell LH and Weinert TA: Checkpoints:
Controls that ensure the order of cell cycle events. Science.
246:629–634. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu
Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and
Skolnick MH: A cell cycle regulator potentially involved in genesis
of many tumor types. Science. 264:436–440. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu M, Wang C, Li Z, Sakamaki T and Pestell
RG: Minireview: Cyclin D1: normal and abnormal functions.
Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weinberg RA: The retinoblastoma protein
and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jung YJ, Lee KH, Choi DW, Han CJ, Jeong
SH, Kim KC, Oh JW, Park TK and Kim CM: Reciprocal expressions of
cyclin E and cyclin D1 in hepatocellular carcinoma. Cancer Lett.
168:57–63. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li T, Zhao X, Mo Z, Huang W, Yan H, Ling Z
and Ye Y: Formononetin promotes cell cycle arrest via
downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer
cells. Cell Physiol Biochem. 34:1351–1358. 2014. View Article : Google Scholar : PubMed/NCBI
|
